<DOC>
	<DOCNO>NCT00836654</DOCNO>
	<brief_summary>The study perform obtain efficacy safety data order obtain marketing authorization ( pivotal study ) . In addition , health economic data collect .</brief_summary>
	<brief_title>Study EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus Untreated Control Group</brief_title>
	<detailed_description />
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>histological confirm diagnosis cancer symptomatic malignant ascites EpCAM positive tumor EOCG 02 negative pregnancy acute chronic infection exposure investigational product , cancer chemo radiotherapy within last 28 day previous treatment mouse monoclonal antibody know suspected hypersensitivity Removab similar antibody inadequate renal function inadequate hepatic function ( AST , ALt , GTP , &lt; x ULN ; bilirubin &lt; 1.5xULN ) Platelets &gt; 80000 cells/mm3 ; absolute neutrophil count ( ANC ) &lt; 1500 cells/mm3 BMI &lt; 17 Patients reduce nutritional status Ileus within last 30 day Brain metastasis cancer history Pregnant nursing woman history myocardial infarction , congestive heart failure relevant cardiac arrhythmia within previous 3 month inadequate respiratory function option investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>EpCAM positive tumor</keyword>
	<keyword>malignant ascites</keyword>
	<keyword>intraperitoneal</keyword>
</DOC>